Former US President Donald Trump is negotiating with Novo Nordisk to offer weight-loss drugs at just $149. Discover how this could revolutionize affordable healthcare and impact India's growing obesity crisis.
Discover how one woman transformed her life by losing 70kg without relying on willpower alone. Her surprising revelation about what really causes weight gain will change everything you thought you knew about dieting.
Breaking news: US FDA approves Rybelsus, the groundbreaking oral weight loss medication that mimics popular injection drugs. Discover how this pill could revolutionise obesity treatment in India and worldwide.
Explore how revolutionary weight-loss medications like Ozempic are transforming lives while raising crucial questions about accessibility, side effects, and long-term sustainability in the Indian context.
Discover the hidden connection between rapid weight fluctuations and kidney damage. Learn about risk factors, prevention tips, and when to seek medical help.
Discover the surprising medical conditions that could be causing your breathlessness during simple walks. Learn when to seek medical attention for this common symptom.
Bengaluru medical experts sound alarm on diabetes drugs being misused for weight loss, highlighting dangerous side effects and long-term health risks.
Eli Lilly is developing Orforglipron oral pills for weight loss and type 2 diabetes that could replace injections, making treatment more accessible and convenient for millions.
Pharmaceutical giant Eli Lilly raises full-year profit forecast as demand skyrockets for revolutionary weight-loss treatment Zepbound, sending shares climbing 7%.
Acanthosis Nigricans, the dark skin patch on children's necks, is emerging as a visible warning sign of India's growing childhood obesity crisis and early diabetes risk.
Discover how revolutionary GLP-1 medications including Ozempic, Wegovy, and Mounjaro are transforming America's battle against obesity, offering new hope for sustainable weight loss.
Former Novo Nordisk CEO Lars Fruergaard Jørgensen reveals why revolutionary weight-loss drugs need comprehensive healthcare strategies to tackle obesity effectively. Discover the missing pieces in the fight against this global epidemic.
India faces a dual health crisis as obesity rates surge alongside undernutrition, creating a massive economic burden that threatens national productivity and healthcare systems.
Discover how excess weight secretly damages your skin elasticity, causes hair thinning, and triggers premature aging. Expert insights on the surprising connection between weight and beauty.
Groundbreaking research shows popular weight-loss drug semaglutide significantly reduces heart disease risk, offering dual benefits for patients struggling with obesity and cardiovascular health.
Discover the surprising daily routines that are sabotaging your weight loss goals. From sleep patterns to eating speed, learn how to break these obesity-triggering habits.
India implements strict new AI regulations targeting deepfakes and misinformation, making social media companies legally responsible for harmful content on their platforms.
Groundbreaking research from Pune reveals diabetes drug semaglutide significantly reduces cardiovascular risks in non-diabetic patients, offering dual benefits for weight and heart health.
India's health ministry introduces strict new regulations for gene therapy and stem cell treatments, aiming to curb unproven medical procedures while advancing legitimate research for conditions like cancer and rare diseases.
MEITY's new directive requires all AI platforms to label AI-generated content, marking India's first major regulatory move to combat deepfakes and digital misinformation.
MEITY mandates clear labeling for AI-generated content in India's groundbreaking move to combat deepfakes, misinformation, and protect digital consumers. New advisory requires platforms to ensure transparency.
In a groundbreaking move, Eli Lilly partners with Cipla to dramatically expand availability of innovative weight loss therapies across India, addressing the growing obesity crisis.
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Pharma giant Eli Lilly collaborates with Indian partner Cipla to introduce groundbreaking obesity and diabetes treatments Mounjaro and Yurpeak in the Indian market, expanding access to innovative weight management solutions.
New medical research reveals shocking connection between modern lifestyle habits and rising cancer rates among adults under 50. Learn how obesity, sedentary routines, and dietary choices are creating a health crisis.
Indian pharmaceutical leader Biocon Biologics partners with Civica to disrupt US insulin market with affordable alternatives, while also eyeing anti-obesity therapy opportunities.
Groundbreaking research reveals a disturbing surge in obesity-related cancers affecting Indians across all age groups. Learn which cancers show the strongest connection and what experts recommend for prevention.
Your daily digest of essential Indian news: From political developments in Maharashtra to cricket updates, Bollywood buzz, and important health guidelines - stay informed in 5 minutes.
Discover why some obese individuals remain metabolically healthy while others develop serious conditions. Learn about fat distribution, lifestyle factors, and prevention strategies from medical experts.
Discover why being thin doesn't mean you're healthy. Learn about 'skinny fat' - the silent threat increasing heart disease risk among Indians with normal BMI.